GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BGLAF) » Definitions » Net Cash per Share

BGLAF (BioGaia AB) Net Cash per Share : $0.82 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). BioGaia AB's Net Cash per Share for the quarter that ended in Dec. 2024 was $0.82.

The historical rank and industry rank for BioGaia AB's Net Cash per Share or its related term are showing as below:

BGLAF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.77   Med: 20.43   Max: 121.29
Current: 11.14

During the past 13 years, the highest Price-to-Net-Cash Ratio of BioGaia AB was 121.29. The lowest was 6.77. And the median was 20.43.

BGLAF's Price-to-Net-Cash is ranked worse than
60.53% of 266 companies
in the Drug Manufacturers industry
Industry Median: 8.4 vs BGLAF: 11.14

BioGaia AB Net Cash per Share Historical Data

The historical data trend for BioGaia AB's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Net Cash per Share Chart

BioGaia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 1.34 1.19 1.20 0.82

BioGaia AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.20 1.22 0.64 0.80 0.82

Competitive Comparison of BioGaia AB's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Price-to-Net-Cash falls into.


;
;

BioGaia AB Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

BioGaia AB's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(111.423-28.227-0)/101.162
=0.82

BioGaia AB's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

Net Cash per Share (Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(111.423-28.227-0)/101.162
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (OTCPK:BGLAF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


BioGaia AB Net Cash per Share Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB Business Description

Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB Headlines

From GuruFocus

Q4 2019 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2020 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2020 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2024 Biogaia AB Earnings Call Transcript

By GuruFocus News 02-13-2025

Q4 2023 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-10-2024

Q4 2021 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2019 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2019 Biogaia AB Earnings Call Transcript

By GuruFocus Research 02-12-2024